PreCanMed is an Italian-Austrian cross-border collaboration.
We study cancer and develop new solutions to advance knowledge and personalize treatment.
We develop one of the most advanced research technology: patient derived tumor organoids, minuscule diseased organs-in-a-dish, unprecedented tools to tackle tumor heterogeneity.
We facilitate experimentation of personalized therapeutic approaches, by deploying tumor organoids to obtain information on molecular features and drug sensitivity of tumors on single patient basis.
We collect and bank patient derived tumor organoids and associated data. The PreCanMed tumor organoid Biobank will foster basic and translational, collaborative cancer research.
Chips of diseased tissues will be taken from tumors during surgery and sent to PreCanMed labs. We focus on breast, lung and colon cancers, top three tumors in the list of the most frequent neoplasia affecting men and women. Moreover, we also address mesothelioma.
Collected tumor samples will be subjected to different procedures in order to identify and define the best conditions enabling growth and expansion of organoid systems.
Developed organoids will be 3D structures incorporating key molecular features of the patient’s tumor of origin. They will be characterized by exome sequencing and gene expression profiling.
Data obtained from tumor organoids will be used to find associations between peculiar molecular features and patient’s response to treatments. Knowing this kind of information is useful to make predictions on treatment efficacy and to guide the therapeutic choice or the search for more effective strategies.
Anti-tumor effects of different candidate drugs resulting from therapy design will be tested on tumor organoids.
Patients’ tumor organoids will be collected and properly stored for subsequent re-expansion and reuse in research.
Modify organoids, test therapies and understand the genomics of tumor organoids!
On the upcoming January 25, Udine will host the second public appointment with PreCanMed and precision anti-cancer medicine.
PreCanMed partners will meet asbestos exposed people and other stakeholders at the V Conference on asbestos next November 23, in Trieste.
A new study on cancer model systems published online today on Nature Genetics.
Together without borders
to tackle the cancer challenge